Skip to content
Life Sciences Series A Founded 2021

RONA Therapeutics

RONA Therapeutics develops oligonucleotide therapeutics to treat metabolic diseases, neurological diseases, and ophthalmology conditions. The company focuses on the discovery and development of modular and programmable RNA medicines using proprietary delivery systems that enable targeted delivery of RNA-based therapeutics to specific tissues and cell types. Founded in 2021 and headquartered in Shanghai, China, RONA…

📍 Shanghai, China · Gene Therapy,

Funding snapshot

Last roundSeries A
Amount$35M
Date19 July 2024
Total raised$68M
Team size19

About

RONA Therapeutics develops oligonucleotide therapeutics to treat metabolic diseases, neurological diseases, and ophthalmology conditions. The company focuses on the discovery and development of modular and programmable RNA medicines using proprietary delivery systems that enable targeted delivery of RNA-based therapeutics to specific tissues and cell types. Founded in 2021 and headquartered in Shanghai, China, RONA Therapeutics has raised $68M in Series A funding from investors including LongRiver Investments, BioTrack Capital, Lilly Asia Ventures, CMB International Capital, Fontus Capital, and LanTing Capital. The company employs 19 people and leverages advances in RNA chemistry and delivery technology to develop therapeutics that can modulate gene expression with high specificity, addressing diseases where traditional small molecule and antibody drugs have limited efficacy.

Business model

Genomics > Applied Genomics > Clinical Genomics > Therapeutics

Institutional investors

LongRiver Investments BioTrack Capital Zhongqi Capital LAV Asset Management Lilly Asia Ventures CMB International Capital Platanus Fontus Capital LanTing Capital

Latest coverage

No articles yet.

Raising like RONA Therapeutics?

Analyze your pitch deck before your next raise.

Analyze My Deck →